Table of Contents
ISRN Hepatology
Volume 2013 (2013), Article ID 702167, 9 pages
http://dx.doi.org/10.1155/2013/702167
Review Article

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012

1Oncology Division, Hospital de Santa Maria, Lisbon, Portugal
2Instituto de Medicina Molecular, University of Lisbon, Portugal
3Radiology Division, Hospital de Santa Maria, Lisbon AV Professor Egas Moniz, 1649-039 Lisbon, Portugal

Received 20 December 2012; Accepted 8 January 2013

Academic Editors: A. Castiella, A. Kutup, and A. Nanashima

Copyright © 2013 Daniela Macedo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors.